Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Appropriate Antibiotic Use for Acute Otitis Media
Your Article Summary
See Latest ArticlesClass III β-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma
Annals of Oncology, 05/28/09
Koh Y et al. - In a study to analyze the significance of class III β-tubulin (TUBB3) expression along with p53 and ERCC1 in locally advanced head and neck squamous cell carcinoma (HNSCC) pts receiving cisplatin-based induction chemotherapy, it appears that TUBB3 is a predictive and prognostic marker along with well-known p53 in HNSCC pts receiving cisplatin-based induction chemotherapy. Clinical impact of ERCC1 is not evident in this setting.
Methods- Retrospective review of medical records at Seoul National University Hospital between 1998 and 2007 was carried out.
- Immunohistochemical stain of TUBB3, p53, and ERCC1 was done in paraffin-embedded tumor tissue.
- Response to treatment, progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS) were assessed.
- 85 pts with oropharyngeal, hypopharyngeal, and laryngeal cancers received induction chemotherapy with 5-fluorouracil (5-FU) and cisplatin (n = 55), or 5-FU, cisplatin, and docetaxel.
- 83 received definitive treatment after induction chemotherapy, where 62 received radiotherapy and 21 received surgery.
- TUBB3-positive pts showed lower response rate than TUBB3-negative pts (69% vs 88%).
- Shorter median PFS was observed in TUBB3-positive group (12 vs 47 mos).
- Shorter median OS was observed in TUBB-positive group not reaching statistical significance (30 vs 59 mos).
- TUBB3 status significantly influenced CSS (35 mos vs not reached).
- Positive p53 status was related to poorer OS and CSS.
- ERCC1 showed no influence on chemotherapy response, PFS, OS, and CSS.
Related Articles
Accelerated fractionation radiotherapy and late intensification with 2 intra-arterial cisplatin infusions for locally advanced head and neck squamous cell carcinoma
Head & Neck, 11/04/09
Relevance Score: 98%
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial
Journal of Clinical Oncology, 11/25/09
Relevance Score: 97%
Changes in Perfusion CT of Advanced Squamous Cell Carcinoma of the Head and Neck Treated during the Course of Concomitant Chemoradiotherapy
American Journal of Neuroradiology, 11/10/09
Relevance Score: 96%
A comparative review of the potential role of adenovirus and Herpes Simplex Virus in the treatment of advanced squamous cell carcinoma of the head and neck
Journal of Radiotherapy in Practice, 11/18/09
Relevance Score: 95%
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
Annals of Oncology, 11/10/09
Relevance Score: 95%
Today in Head and Neck...keeping you current
Receive free subspecialty "5-minute updates" via email
Secondary surgery in paediatric facial paralysis reanimation
Journal of Plastic, Reconstructive & Aesthetic Surgery, 12/18/09
Dizziness and vertigo in an older population: the Blue Mountains prospective cross-sectional study
Clinical Otolaryngology, 12/18/09
When will I see you again? Using local recurrence data to develop a regimen for routine surveillance in post-treatment head and neck cancer patients
Clinical Otolaryngology, 12/18/09
Article Search
Sponsor